Use of Insulin Pump in Children with Type I Diabetes Mellitus: Effect on glycemic control and Body Mass Indices (BMI). Noura Al Hemaidi, Maryam Al Ali,

Slides:



Advertisements
Similar presentations
Nallasamy K, Jayashree M, Singhi S, Bansal A
Advertisements

Managing T2DM during Ramadan Dr. Asrar Said Hashem Specialist in Internal Medicine (Al-Amiri Hospital) Fellow of KIMS Endocrine, Diabetes and Metabolism.
Farxiga™ - Dapagliflozin
Diabetes Mellitus.
Insulin Pump What to tell your patient!! Prakash Abraham Isla Fairley.
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus Matthew Faiman.
Presented by Dr. Soe Sandi Tint
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
Diabetes in Pediatrics Understanding Type I and Type II Diabetes in Children and Adolescents By: Erica Glover.
Racial Differences in the Impact of HMO Coverage of Diabetes Blood Glucose Monitors on Self-Monitoring Connie A. Mah, M.S. Department of Ambulatory Care.
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

Dr. Turki AlBatti,MD. barriers in young adults with type 1 diabetes Glycemic control and adherence behaviors remain low for patients with type 1 diabetes.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 3 of 3.
THE INSULIN PUMP INNOVATIVE TECHNOLOGIES. WHAT IS AN INSULIN PUMP? Machine delivery of insulin. Most commonly for those with Type one diabetes.
TALK DIABETES November 13, 2015 Pumping Insulin 101 Bonnie Stone-Hope RN, CDE, BA.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
By: Kristin Izzo, Intern Preceptor: Mary M. Julius, RD, LD, CDE and Neal Kurmas, MS, RD, LD, CDE.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
Spring  There are two types of diabetes ◦ Type 1 and 2  Blood sugar is involved  Insulin is involved  You might need to take your blood sugar.
Medical Management of Diabetes During Ramadan Jennifer Hamilton, MD August, 2007 CE Rajab, 1428 AH.
TEMPLATE DESIGN © CONTINUOUS GLUCOSE MONITORING, ORAL GLUCOSE TOLERANCE, AND INSULIN – GLUCOSE PARAMETERS IN ADOLESCENTS.
Background Type your answer / solution here Write hypothesis before you begin the experiment This should be your best educated guess based on your research.
Background Type your answer / solution here Write hypothesis before you begin the experiment This should be your best educated guess based on your research.
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
A two stage screening process – the pre-diabetes pathway.
TYPE 1 DIABETES UPDATE Colorado Association for School-Based Health Care G. Todd Alonso, MD May 6, 2016.
Brigham and Women’s Hospital Center for Clinical Investigation
Baseline characteristics
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
Nallasamy K, Jayashree M, Singhi S, Bansal A
HbA1c before Ramadan (%)
Diabetic hypoglycemia from prevention to management.
GLUCOSE TOLERANCE TEST (GTT)
Neal B, et al. Diabetes Care 2015;38:403–411
Copyright © 2004 American Medical Association. All rights reserved.
Insulin Detemir versus Glyburide in Women with
Structured Education for Type 2 diabetes: expensive and unproven?
Therapy of Type 2 Diabetes Mellitus: UPDATE
Endocrine System KNH 411.
Cardiometabolic Health Check
Endocrine System KNH 411.
Diabetes and Risk of CV Outcomes
Nutrition & Dietetic Service to Patients with Diabetes in West Berkshire Carolyn Jones Dietetic Team Lead.
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
New Patient-Friendly Options for Managing Insulin Dosing
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Examining CV Effects of Basal Insulin Therapy
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Endocrine System KNH 411.
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
DiRECT (Diabetes Remission Clinical Trial)
Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Dual SGLT1/SGLT2 Inhibition in T1D
Endocrine System KNH 411.
Campbell FM, et al. Pediatr Diabetes. 2018;19(7):1294–1301
Lecture 3 Endocrine and Metabolic Disorders “Obesity”
Endocrine System KNH 411.
Endocrine System KNH 411.
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
PowerPoint 16:9 Screen Ratio Template *
Postoperative blood glucose levels and total insulin requirement.
Presentation transcript:

Use of Insulin Pump in Children with Type I Diabetes Mellitus: Effect on glycemic control and Body Mass Indices (BMI). Noura Al Hemaidi, Maryam Al Ali, Ashraf Soliman, Mahmmoud AlZyoud The Departments of Pediatrics, Hamad Medical Center , Doha, Qatar Introduction -Patients RESULTS Discussion Experience with the pump in children however is still in its primary phase. Controlled randomized studies in children are still very few. In addition, the use of insulin pump in our cohort of diabetic children needs a thorough investigation to decide about the benefits versus the disadvantages in our culture and hospital set-up . Inclusion criteria: All children with DM 1, < 14 yr, who were on insulin pump (Medtronic) for one year or more. Exclusion criteria : Insulin pump less than one year, other types of diabetes mellitus, renal or hepatic impairment, malnutrition (primary or secondary) or any other systemic illness In this retrospective study all children <14 yr (n=23) with DM1,who were started on insulin pump, have been followed for one year or more in the diabetes clinic at Hamad Medical Center (HMC) In this study, the HbA1c concentration decreased significantly after using the pump in 18 children . 5 patients showed deterioration, 3 of them didn’t use carbohydrate counting properly, 1had phobia from hypoglycemia. BMI increased significantly in all patients after the pump in both the well-controlled and poorly-controlled groups ( p >0.05) this weight gain is due to the anabolic effect of the near-physiologically delivered insulin through the pump. However the BMI of 22/23 patients did not exceeded the 85th % . Good dietary management and intensive education about carbohydrate count should decrease the risk of weight gain in these patients. Three of them developed one incidence of DKA, due to pump malfunctioning ( n= 2), or patient error. After reeducation, no DKA was recorded. 3 who were developing recurrent hypoglycemia before the pump, had no hypoglycemic attack after the pump. Summary the effect of insulin pump on the glycemic control and BMI of 23 children with type 1 DM1 showed that after starting the pump, HbA1c concentration deceased from (9.36+/-2.02%) to (8.54+/-1.149%).The BMI increased significantly from (17.12+/-2.236) to (20.4+/-2.93). No incidence of hypoglycemia was reported in any of the patients. Three incidences of DKA were reported after the pump due to pump mal-functioning(n=2) or patient error (n=1). All patients except two showed interest to continue the pump because of desirable flexibility of their lifestyle including activity and meal times Data Collection included: Anthropometric data: weight, height, and BMI, Biochemical data: HbA1c Frequency of incidence/s of DKA and symptomatic hypoglycemia before vs after the pump Frequency of blood glucose monitoring per day. Three incidences of DKA was reported due to pump malfunction( n=2) and patient error(n=1). No symptomatic hypoglycemia was reported . The quality of life as judjed by the patients and Parents showed ood satisfaction because of improvement of the quality and quantity of daily activity and flexibility of food intake .